Glucocorticoid Therapy in Rheumatoid Arthritis

摘要: Discovered over 50 years ago, synthetic cortisone was first shown to be remarkably effective in relieving the inflammation associated with rheumatoid arthritis (RA) (1,2). This pioneering work by Hench, Kendall, and colleagues subsequently resulted a Nobel Prize Medicine. Today, glucocorticoid use RA remains one of most controversial commonly debated areas modern management (3–8). Attitudes towards range from disdain (6,9) widespread acceptance (3,5). Despite this contentiousness, it is widely agreed that moderate- or high-dose therapy highly controlling acute inflammation, but may result significant serious adverse events. In addition their recognized short-and medium-term efficacy for disease activity, increasing evidence favors potential modifying effect these agents. Lastly, controversy continues surround toxicity low-dose RA, particularly its effects on bone.